Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Gilead Sciences, Inc
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus) and Peginterferon Alfa 2a (Pegasys) in Treatment Na�ve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection
The primary objective of this study is to evaluate the antiviral efficacy (sustained virologic response [SVR]; defined as undetectable HCV RNA 24 weeks following treatment cessation) of 16 and 24 week...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A trial investigating the safety and efficacy of a drug combination Sofosbuvir/Velpatasvir for subjects with hepatitis C
To evaluate the efficacy of study treatment with sofosbuvir (SOF)/velpatasvir (VEL) FDC for 12 weeks as measured by the proportion of subjects with sustained virologic response 12 weeks after cessatio...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
An investigational study to assess the safety and efficacy of a new investigational drug in subjects with compensated liver cirrhosis secondary to non-alcoholic steatohepatitis (NASH)
To evaluate whether simtuzumab (formerly referred to as GS-6624) can reduce portal venous pressure and incidence of clinical events in subjects with cirrhosis due to NASH.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A long-term study to follow cirrhotic patients infected with chronic Hepatitis C who achieved a cure following treatment in a Gilead clinical trial
To assess the durability of SVR; To assess clinical progression or regression of liver disease, including the incidence of hepatocellular carcinoma (HCC) following SVR.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A study to evaluate the effects of the combination of 4 oral antiviral agents for the treatment of patients infected with the Hepatitis C Virus (HCV)
To evaluate the antiviral efficacy as measured by sustained virologic response (SVR, defined as HCV RNA < LLoQ 24 weeks post-treatment) of 30 mg or 90 mg GS-5885 when given with GS-9451, tegobuvir and...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
This trial will test the drug filgotinib for the treatment of small bowel Crohn’s disease
The primary objective of this study is to evaluate the efficacy of filgotinib, when compared to placebo, in establishing clinical remission at Week 24
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
Study to Evaluate GS-5806 in Volunteers Infected with Respiratory Syncytial Virus
The primary objective of the study is to evaluate the antiviral effect of GS-5806 in healthy adults infected with RSV-A Memphis 37b (RSV).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A study is to see if HIV-1 positive subjects currently taking an antiretroviral (ARV) regimen consisting of EVG/COBI/FTC/TDF (E/C/F/TDF) STR, Atripla® (also known as Sustiva®), cobicistat and atazanavir with Truvada® or ritonovir and atazanavir with Truvada® can safely switch to E/C/F/TAF STR without increasing the amount of HIV-1 in their blood
The primary objective of this study is: • To evaluate the non-inferiority of switching to a TAF-Containing STR relative to maintaining TDF-Containing Regimens in Virologically-Suppressed HIV-1 positi...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. Estudio para evaluar la seguridad y eficacia de selonsertib en pacientes con esteatohepatitis no alcohólica (EHNA) y fibrosis en puentes (F3)
The primary objective of this study is: To evaluate whether SEL can cause fibrosis regression and reduce progression to cirrhosis and associated complications in subjects with NASH and bridging (F3) f...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A study evaluating the safety and efficacy of the combination of GS-4059 and idelalisib with and without obinutuzumab in subjects with chronic lymphocytic leukemia
The primary objective of this study is to determine the preliminary efficacy of the combination of GS-4059 and idelalisib with and without obinutuzumab in subjects with relapsed or refractory CLL
Country
None
organs
None
Specialty
None
unknown
More information
Previous
4
5
6
7
8
9
10
11
12
13
Next